What are the average monthly and yearly costs for Wegovy without insurance?
Wegovy’s list price stands at $1,350 for a 28-day supply, or roughly $16,200 per year. Most patients pay far less once insurance, savings cards, or manufacturer coupons apply, but cash-pay pricing remains the benchmark for financial planning.
How much does insurance typically cover for Wegovy prescriptions?
Commercial plans that cover anti-obesity medications reimburse 50–80 % of the cost for eligible patients, bringing out-of-pocket amounts down to a few hundred dollars per month. Medicare Part D still excludes weight-loss drugs, leaving seniors to pay full price or seek alternative coverage.
Can patients use savings cards or coupons to reduce the price of Wegovy?
Novo Nordisk’s savings card lowers the copay to as little as $25 per month for commercially insured patients who meet eligibility rules. Uninsured or cash-pay users can access a separate $499 monthly program that still leaves a substantial annual expense.
What happens to costs once the Wegovy patent expires?
The key U.S. patent covering semaglutide formulations runs until at least 2032, so near-term generic or biosimilar competition is unlikely. Earlier patent challenges or regulatory changes could shift pricing sooner, but current exclusivity keeps list prices elevated.
How do long-term medical savings from weight loss compare with Wegovy’s drug cost?
Modeling studies estimate that sustained 15 % body-weight reduction can cut annual diabetes, hypertension, and cardiovascular care costs by $2,000–$4,000 per patient. Over five to ten years these avoided expenses can exceed Wegovy’s cumulative price, producing a net financial gain for both patients and payers.
Are there lower-cost alternatives that deliver similar weight-loss results?
Compounded semaglutide from certain pharmacies currently sells for $200–$400 per month, but quality, dosing accuracy, and regulatory oversight vary. Older agents such as phentermine or generic orlistat cost under $100 monthly yet produce far smaller average weight reductions.
What out-of-pocket expenses should patients anticipate beyond the drug itself?
Follow-up visits, lab monitoring, and potential dose-adjustment consultations can add several hundred dollars annually. Some plans require prior authorization or step therapy, introducing administrative costs and occasional treatment delays.
How does Wegovy’s cost-effectiveness stack up against bariatric surgery?
Sleeve gastrectomy or gastric bypass carry one-time surgical fees of $15,000–$30,000, but they often eliminate the need for lifelong medication. Cost-effectiveness analyses show surgery overtakes Wegovy on a five-year horizon for patients with BMI above 40 who qualify.
[1] https://www.drugpatentwatch.com/drug/wegovy